Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.

Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.

Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.

Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).

Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Abstract: A hearing aid (100) having a microphone, a signal processing unit, an electrical-acoustical output transducer, a housing (101) and a wind shield cover (102) wherein the housing has a surface with a microphone inlet (112, 113), and the wind shield cover is adapted to be attached to the housing, to cover the microphone inlet, to provide for sound to be guided in a gap between the wind shield cover and the housing, hereby providing for the transmission of sound from the surroundings and to said microphone inlet, wherein a first dimension of a cross-section of the gap is in the range between 0.15 mm and 0.5 mm, and wherein the minimum distance, along the gap, from the microphone inlet and to the opening of the gap, towards the surroundings, is at least 1 mm.

Abstract: A method of determining a representation of a physical property of a finger using a finger sensing system comprising a two-dimensional measuring arrangement including a plurality of measuring elements, each defining a measuring element position in the measuring arrangement, and each comprising a finger electrode spaced apart from the finger by a dielectric structure.

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Abstract: The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.

Abstract: The present invention relates to antibodies specific for pyroglutamated A?, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands. Further, is provided pyroglutamated N-terminal fragments of murine or human A? to generate antibodies and for use in therapeutic purposes.

Abstract: The present disclosure relates to antibodies specific for pyroglutamated A?, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands Further, is provided pyroglutamated N-terminal fragments of murine or human A? to generate antibodies and for use m therapeutic purposes.

Abstract: The present disclosure relates to antibodies specific for pyroglutamated A?, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands Further, is provided pyroglutamated N-terminal fragments of murine or human A? to generate antibodies and for use m therapeutic purposes

Abstract: A navigation system includes a hearing device configured to be head worn and having loudspeakers for emission of sound towards ears of a user; a GPS unit for determining a geographical position of the system; a sound generator connected for outputting audio signals to the loudspeakers; and a processor configured for selecting Points-Of-Interest in a vicinity of the system, and controlling the sound generator to output the audio signals that represents spoken information on the selected Points-Of-Interest in sequence.

Abstract: A navigation system includes: a hearing device configured to be head worn and having loudspeakers for emission of sound towards ears of a user, and accommodating an inertial measurement unit for determining head yaw, when the user wears the hearing device in its intended operational position on the user's head; a GPS unit for determining a geographical position of the system; a sound generator connected for outputting audio signals to the loudspeakers; and a processor configured for: selecting a POI in a forward looking direction of the user based on the determined head yaw, and controlling the sound generator to output the audio signals that represent spoken information on the selected POI.

Abstract: A navigation system includes a hearing device configured to be head worn and having loudspeakers for emission of sound towards ears of a user; a GPS unit for determining a geographical position of the system; a sound generator connected for outputting audio signals to the loudspeakers; and a processor configured for selecting Points-Of-Interest in a vicinity of the system, and controlling the sound generator to output the audio signals that represents spoken information on the selected Points-Of-Interest in sequence.